GlassScriptPhysician profile
Keith R Brill
NPI 1598764771
$2,865.20
in general payments reported to CMS, 2019-2025
40 companies · $282 in 2025
The $282 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $475 · 2020: $377 · 2021: $460 · 2022: $497 · 2023: $518 · 2024: $256 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,036 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,036.30 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $596.02 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Mayne Pharma Commercial LLC | $238.80 | 2022-2025 | |
| Hologic Sales and Service, LLC | $205.67 | 2019-2025 | Myosure Tissue Removal Device, Aptima, Thinprep 2000 Processor |
| Therapeuticsmd, INC. | $203.63 | 2019-2022 | |
| Minerva Surgical, INC | $181.07 | 2019-2023 | |
| Astellas Pharma US INC | $129.56 | 2023-2025 | Veozah |
| Coopersurgical, INC. | $129.21 | 2019-2025 | Onetrac Lx |
| Exeltis, USA INC. | $109.84 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.99 | 2019-2023 | |
| Allergan, INC. | $67.81 | 2019-2020 | |
| Daiichi Sankyo INC. | $64.55 | 2020-2024 | Injectafer |
| Organon LLC | $62.79 | 2022-2024 | Nexplanon |
| Pfizer INC. | $55.46 | 2021-2024 | |
| Viiv Healthcare Company | $50.15 | 2023 | Apretude |
| Momentis Surgical INC. | $48.00 | 2022 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $43.13 | 2024-2025 | Zurzuvae |
| Avion Pharmaceuticals | $42.23 | 2019-2023 | Balcoltra |
| Baxter Healthcare | $39.91 | 2020 | |
| Amag Pharmaceuticals, INC. | $39.30 | 2019-2020 | |
| Lupin INC. | $37.60 | 2019-2020 | |
| Medicem INC. | $36.49 | 2021-2022 | |
| Agile Therapeutics, INC. | $35.38 | 2022 | |
| Pharmacosmos Therapeutics INC. | $35.17 | 2021-2022 | |
| Qiagen, LLC | $33.56 | 2025 | |
| Biom'Up Sa | $27.30 | 2019 | |
| Millicent US INC | $25.11 | 2025 | Femlyv |
| Novo Nordisk INC | $24.85 | 2022 | |
| Shield Therapeutics INC | $23.38 | 2025 | |
| Axonics, INC. | $21.96 | 2023 | Bulkamid, Axonics |
| Myovant Sciences INC. | $20.52 | 2022 | |
| Medicomp INC | $17.42 | 2019 | |
| Aspira Women'S Health INC | $17.36 | 2024 | Ova1 |
| Mylan Pharmaceuticals INC. | $16.20 | 2021 | |
| Uroviu Corporation | $15.93 | 2022 | |
| Kci USA, INC. | $15.49 | 2020 | |
| Covidien LP | $15.37 | 2020 | |
| Ethicon US, LLC | $14.27 | 2019 | |
| Exact Sciences Corporation | $13.47 | 2024 | Cologuard Collection Kit |
| C. R. Bard, INC. & Subsidiaries | $13.37 | 2023 | Bd Onclarity |
| Merck Sharp & Dohme LLC | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Brill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.